UNITED THERAPEUTICS Corp (UTHR) stock
UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3020% above fair value
$554.73−4.37 (-0.78%)
Close on Nov 20, 2026Market cap $23.79BP/E 19.8Yield –
United Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
United Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $1.09B, up 2.1% year over year. For fiscal 2025 it was $1.04B, down 3.7% from the year before. Over ten years it grew 12.1% a year on average. The highest annual figure on record is $1.08B in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.04B | -3.7% |
| FY2024 | Dec 31, 2024 | $1.08B | +44.5% |
| FY2023 | Dec 31, 2023 | $747.60M | +12.6% |
| FY2022 | Dec 31, 2022 | $663.70M | +39.0% |
| FY2021 | Dec 31, 2021 | $477.40M | -31.4% |
| FY2020 | Dec 31, 2020 | $696.40M | – |
| FY2019 | Dec 31, 2019 | -$290.30M | -148.9% |
| FY2018 | Dec 31, 2018 | $594.00M | +53.1% |
| FY2017 | Dec 31, 2017 | $387.90M | -35.9% |
| FY2016 | Dec 31, 2016 | $605.60M | +81.9% |
| FY2015 | Dec 31, 2015 | $333.00M | +8.2% |
| FY2014 | Dec 31, 2014 | $307.90M | -21.7% |
| FY2013 | Dec 31, 2013 | $393.36M | +85.8% |
| FY2012 | Dec 31, 2012 | $211.72M | -1.2% |
| FY2011 | Dec 31, 2011 | $214.22M | +11.1% |
| FY2010 | Dec 31, 2010 | $192.89M | +4362.0% |
| FY2009 | Dec 31, 2009 | $4.32M | – |
| FY2008 | Dec 31, 2008 | -$164.84M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $205.60M | +58.8% |
| Q1 FY2026 | Mar 31, 2026 | $362.50M | -6.2% |
| Q4 FY2025 | Dec 31, 2025 | $173.30M | -31.9% |
| Q3 FY2025 | Sep 30, 2025 | $351.60M | +16.9% |
| Q2 FY2025 | Jun 30, 2025 | $129.50M | -30.8% |
| Q1 FY2025 | Mar 31, 2025 | $386.30M | +14.2% |
| Q4 FY2024 | Dec 31, 2024 | $254.50M | +253.5% |
| Q3 FY2024 | Sep 30, 2024 | $300.70M | +7.2% |
| Q2 FY2024 | Jun 30, 2024 | $187.10M | +203.7% |
| Q1 FY2024 | Mar 31, 2024 | $338.30M | +1.4% |
| Q4 FY2023 | Dec 31, 2023 | $72.00M | -18.8% |
| Q3 FY2023 | Sep 30, 2023 | $280.50M | +47.8% |
| Q2 FY2023 | Jun 30, 2023 | $61.60M | -44.0% |
| Q1 FY2023 | Mar 31, 2023 | $333.50M | +21.2% |
| Q4 FY2022 | Dec 31, 2022 | $88.70M | -14.7% |
| Q3 FY2022 | Sep 30, 2022 | $189.80M | +16.9% |
| Q2 FY2022 | Jun 30, 2022 | $110.00M | -16.6% |
| Q1 FY2022 | Mar 31, 2022 | $275.20M | +247.5% |
| Q4 FY2021 | Dec 31, 2021 | $104.00M | -8.7% |
| Q3 FY2021 | Sep 30, 2021 | $162.30M | -31.0% |
| Q2 FY2021 | Jun 30, 2021 | $131.90M | -9.5% |
| Q1 FY2021 | Mar 31, 2021 | $79.20M | -60.7% |
| Q4 FY2020 | Dec 31, 2020 | $113.90M | +46.4% |
| Q3 FY2020 | Sep 30, 2020 | $235.10M | +36.8% |
| Q2 FY2020 | Jun 30, 2020 | $145.80M | +29.5% |
| Q1 FY2020 | Mar 31, 2020 | $201.60M | – |
| Q4 FY2019 | Dec 31, 2019 | $77.80M | +131.5% |
| Q3 FY2019 | Sep 30, 2019 | $171.80M | -12.3% |
| Q2 FY2019 | Jun 30, 2019 | $112.60M | -10.8% |
| Q1 FY2019 | Mar 31, 2019 | -$652.50M | -374.0% |
| Q4 FY2018 | Dec 31, 2018 | $33.60M | – |
| Q3 FY2018 | Sep 30, 2018 | $196.00M | -17.1% |
| Q2 FY2018 | Jun 30, 2018 | $126.30M | +153.6% |
| Q1 FY2018 | Mar 31, 2018 | $238.10M | +10.6% |
| Q4 FY2017 | Dec 31, 2017 | -$113.60M | -176.4% |
| Q3 FY2017 | Sep 30, 2017 | $236.50M | +7.7% |
| Q2 FY2017 | Jun 30, 2017 | $49.80M | – |
| Q1 FY2017 | Mar 31, 2017 | $215.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $148.70M | – |
| Q3 FY2016 | Sep 30, 2016 | $219.60M | – |
See a number that looks wrong?